Stem Cell Therapy Market worth $3.65 billion by 2035 | MarketsandMarkets™

DELRAY BEACH, Fla., June 15, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Stem Cell Therapy Market is projected to grow from about USD 0.48 billion in 2026 to USD 3.65 billion by 2035, at a CAGR of 25.3%.

Browse 450 market data Tables and 60 Figures spread through 478 Pages and in-depth TOC on "Stem Cell Therapy Market - Global Forecast to 2035"

Stem Cell Therapy Market Size & Forecast:

• Market Size Available for Years: 2026–2035
• 2026 Market Size: USD 0.48 billion
• 2035 Projected Market Size: USD 3.65 billion
• CAGR (2026–2031): 25.3%

Stem Cell Therapy Market Trends & Insights:

• The induced pluripotent stem cells segment is projected to grow at the highest CAGR between 2026 and 2035.
• The autologous stem cell therapy segment accounted for the largest market share in 2025.
• The musculoskeletal disorders segment accounted for the largest share by therapeutic application in 2025.
• Europe is the fastest-growing regional segment, with a CAGR of 48.3% in the global stem cell therapy market.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=48

The growth of the market is driven by the increasing prevalence of chronic and degenerative diseases, rising investments in regenerative medicine, and expanding clinical trial activities for stem cell-based therapies. Additionally, advancements in induced pluripotent stem cell (iPSC) technologies and the broader adoption of allogeneic stem cell therapy platforms are expected to support market growth.

Technological advancements in cell sourcing, stem cell isolation, ex vivo expansion, closed-system manufacturing, automated cell processing, cryopreservation, potency testing, and high-throughput quality control workflows are making stem cell therapy development and manufacturing more scalable, reproducible, and commercially reliable. These advancements are particularly important for autologous therapies, where patient-specific variability and chain-of-identity control are critical, and for allogeneic therapies, where consistent donor-cell expansion, batch-to-batch comparability, and long-term cell viability are essential for off-the-shelf product supply. Evolving GMP requirements, CMC expectations, donor eligibility standards, sterility controls, potency assay requirements, traceability systems, and post-market safety monitoring frameworks are pushing developers and manufacturers to adopt validated, closed, and contamination-controlled manufacturing platforms.

The tissue-specific stem cell therapy segment accounted for the largest share of the global stem cell therapy market, by cell source, in 2025.

Based on cell source, the stem cell therapy market is segmented into adipose tissue-derived MSCs, bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, induced pluripotent stem cells, embryonic stem cells, tissue-specific stem cells, and other cell sources. In 2025, tissue-specific stem cell therapy accounted for the largest share of the stem cell therapy market because these therapies are more clinically established, better understood, and closer to routine therapeutic use than newer pluripotent stem cell platforms such as iPSCs and embryonic stem cells. Tissue-specific stem cells are already associated with defined therapeutic functions in specific organs or tissues, such as corneal epithelial stem cells for ocular surface repair, hematopoietic stem/progenitor cells for blood and immune reconstitution, chondrocyte/cartilage-related cell therapies for musculoskeletal repair, and epithelial or skin-derived cell therapies for wounds and burns.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=48

Allogeneic stem cell therapy is projected to be the fastest-growing type.

The global stem cell therapy market is segmented by type into allogeneic and autologous stem cell therapies. During the forecast period, the allogeneic stem cell therapy segment is projected to be the fastest-growing segment in the stem cell therapy market, driven by increasing demand for off-the-shelf cell therapy products, scalability of manufacturing processes, and expanding pipeline of allogeneic candidates across multiple therapeutic indications. These therapies provide standardized production and broader patient access essential for clinical and commercial applications. Additionally, the expanding pipeline of allogeneic cell therapy candidates, increasing regulatory approvals, and the growing adoption of advanced cell processing technologies continue to accelerate demand for allogeneic stem cell therapies globally.

North America accounted for the largest regional share in the global stem cell therapy market in 2025.

The stem cell therapy market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. In 2025, North America accounted for the largest share of the global stem cell therapy market, driven by a well-established biopharmaceutical industry, strong investments in regenerative medicine research, and high adoption of advanced cell therapy technologies. The region also benefits from significant R&D spending, expanding clinical trial activities, and a strong presence of leading market players and research institutions. Additionally, favorable funding initiatives and growing demand for stem cell-based regenerative therapies continue to support the region's leadership in the global stem cell therapy market.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=48

Top Companies in Stem Cell Therapy Market:

The Top Companies in Stem Cell Therapy Market include Vericel Corporation (US), Mesoblast (Australia), MEDIPOST (South Korea), JCR Pharmaceuticals Co., Ltd. (Japan), Takeda Pharmaceutical Company Limited (Japan), Anterogen Co., Ltd. (South Korea), CorestemChemon Inc. / Corestem, Inc. (South Korea), Vertex Pharmaceuticals (US), Pharmicell Co., Ltd. (South Korea), Holostem Terapie Avanzate Srl (Italy), Stempeutics Research Pvt. Ltd. (India), Cipla Limited (India), Bayer AG (Germany), Aspen Neuroscience (US), Longeveron Inc. (US), and Smith+Nephew (UK).

Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting

Related Reports:

Biologics Safety Testing Market - Global Forecast to 2031

Autologous Stem Cell & Non-stem Cell Therapies Market - Global Forecast to 2029

Cardiovascular Devices Market - Global Forecast to 2029 

Cell Isolation Market - Global Forecast to 2031

Cell Expansion Market - Global Forecast to 2029

About MarketsandMarkets™ 

MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.

Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.

The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.

MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/